Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapy. uri icon

Overview

publication date

  • March 21, 2017

Research

keywords

  • Lymphoma, Follicular
  • Purines
  • Quinazolinones

Identity

Scopus Document Identifier

  • 85020257653

Digital Object Identifier (DOI)

  • 10.1182/blood-2016-12-757740

PubMed ID

  • 28325864

Additional Document Info

volume

  • 129

issue

  • 22